Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 30 (10), 1436-1441
- https://doi.org/10.1016/0959-8049(94)00276-b
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The effect of three dose levels of ICS 205–930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomitingEuropean Journal of Cancer and Clinical Oncology, 1989
- FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESISThe Lancet, 1987
- Nabilone: an alternative antiemetic for cancer chemotherapy.Archives of Disease in Childhood, 1986
- Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.Journal of Clinical Oncology, 1985
- Paradoxical effects of prophylactic phenothiazine antiemetics in children receiving chemotherapy.Journal of Clinical Oncology, 1984
- Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapyThe Journal of Pediatrics, 1984